https://www.nationalreview.com/corner/major-swedish-hospital-bans-puberty-blocking-for-gender-dysphoria/
The actual science is beginning to overcome transgender ideology. First, the U.K.’s National Institute for Health and Care Excellence — basically the NHS’s decision-maker for what to cover — determined that there was “very low” evidence of benefit to allow children with gender dysphoria to have their natural puberty blocked — which is an “off label” use of those drugs, by the way.
Now, Karolinska Hospital, a major health institution in Sweden, is stopping their use. First, there is little scientific to support such interventions. From the hospital’s official statement:
In December 2019, the SBU (Swedish Agency for Health Technology Assessment and Assessment of Social Services) published an overview of the knowledge base which showed a lack of evidence for both the long-term consequences of the treatments, and the reasons for the large influx of patients in recent years.
Even more importantly, the potential for harming the patient physically is very real:
These treatments are potentially fraught with extensive and irreversible adverse consequences such as cardiovascular disease, osteoporosis, infertility, increased cancer risk, and thrombosis. This makes it challenging to assess the risk/benefit for the individual patient, and even more challenging for the minors and their guardians to be in a position of an informed stance regarding these treatments.
Yikes!
As a consequence the hospital wisely enacted the following policy:
In light of the above, and based on the precautionary principle, which should always be applied, it has been decided that hormonal treatments (i.e., puberty blocking and cross-sex hormones) will not be initiated in gender dysphoric patients under the age of 16.